Access this article Similar content being viewed by others References Coskun T, Sloop KW, Loghin C, et al
More serious but rare side effects may include pancreatitis, gallbladder problems, kidney changes, and low blood sugar
Follow-ups are generally handled through the platform's messaging system
The strongest case is for patients who have failed standard titration at multiple dose levels
The weight management share is projected to decline to 55% by 2035 as cardiovascular risk anchored indications grow to 45% of the market
GLP-1 receptor agonists, or glucagon-like peptide-1 receptor agonists, were first developed to help people with type 2 diabetes manage their blood sugar levels